Hansa Biopharma AB
STO:HNSA

Watchlist Manager
Hansa Biopharma AB Logo
Hansa Biopharma AB
STO:HNSA
Watchlist
Price: 32.24 SEK -1.1% Market Closed
Market Cap: 3.3B SEK

Wall Street
Price Targets

HNSA Price Targets Summary
Hansa Biopharma AB

Wall Street analysts forecast HNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HNSA is 78.54 SEK with a low forecast of 33.33 SEK and a high forecast of 116.55 SEK.

Lowest
Price Target
33.33 SEK
3% Upside
Average
Price Target
78.54 SEK
144% Upside
Highest
Price Target
116.55 SEK
262% Upside
Hansa Biopharma AB Competitors:
Price Targets
PRDO
Perdoceo Education Corp
36% Upside
BCBP
BCB Bancorp Inc
36% Upside
TENB
Tenable Holdings Inc
71% Upside
AMP
Amper SA
12% Upside
UFPT
UFP Technologies Inc
12% Upside
ACAD
ACADIA Pharmaceuticals Inc
18% Upside
MEDP
Medpace Holdings Inc
-9% Downside

Revenue
Forecast

46% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
46% / Year
Past Growth
78% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

For the last 13 years the compound annual growth rate for Hansa Biopharma AB's revenue is 46%. The projected CAGR for the next 4 years is 78%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HNSA's stock price target?
Price Target
78.54 SEK

According to Wall Street analysts, the average 1-year price target for HNSA is 78.54 SEK with a low forecast of 33.33 SEK and a high forecast of 116.55 SEK.

What is Hansa Biopharma AB's Revenue forecast?
Projected CAGR
78%

For the last 13 years the compound annual growth rate for Hansa Biopharma AB's revenue is 46%. The projected CAGR for the next 4 years is 78%.

Back to Top